These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20528879)

  • 21. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
    Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL
    Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.
    Tomasello SD; Angiolillo DJ; Goto S
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1557-67. PubMed ID: 20979570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study).
    Serebruany VL; Miller M; Pokov AN; Malinin AI; Lowry DR; Tanguay JF; Hennekens CH
    Am J Cardiol; 2006 May; 97(9):1332-6. PubMed ID: 16635606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombin receptors and their antagonists: an update on the patent literature.
    Cirino G; Severino B
    Expert Opin Ther Pat; 2010 Jul; 20(7):875-84. PubMed ID: 20450349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo.
    Perez M; Lamothe M; Maraval C; Mirabel E; Loubat C; Planty B; Horn C; Michaux J; Marrot S; Letienne R; Pignier C; Bocquet A; Nadal-Wollbold F; Cussac D; de Vries L; Le Grand B
    J Med Chem; 2009 Oct; 52(19):5826-36. PubMed ID: 19791800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease.
    Chintala M; Shimizu K; Ogawa M; Yamaguchi H; Doi M; Jensen P
    J Pharmacol Sci; 2008 Dec; 108(4):433-8. PubMed ID: 19098390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1.
    Hildemann SK; Bode C
    Hamostaseologie; 2009 Nov; 29(4):349-55. PubMed ID: 19882073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk and benefit of direct oral anticoagulants or PAR-1 antagonists in addition to antiplatelet therapy in patients with acute coronary syndrome.
    Gao F; Shen H; Wang ZJ; Yang SW; Liu XL; Zhou YJ
    Thromb Res; 2015 Aug; 136(2):243-9. PubMed ID: 26037286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
    Moon JY; Franchi F; Rollini F; Angiolillo DJ
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):23-37. PubMed ID: 28565918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.
    Leonardi S; Tricoci P; Becker RC
    Adv Cardiol; 2012; 47():87-99. PubMed ID: 22906905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
    TRA*CER Executive and Steering Committees
    Am Heart J; 2009 Sep; 158(3):327-334.e4. PubMed ID: 19699853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet thrombin receptor antagonism and atherothrombosis.
    Angiolillo DJ; Capodanno D; Goto S
    Eur Heart J; 2010 Jan; 31(1):17-28. PubMed ID: 19948715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tailoring naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and in vitro evaluation.
    Stylos E; Chatziathanasiadou MV; Tsiailanis A; Kellici TF; Tsoumani M; Kostagianni AD; Deligianni M; Tselepis AD; Tzakos AG
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2609-2618. PubMed ID: 28844979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers: smoking, thrombin, and vascular responses in vivo.
    Lang NN; Gudmundsdóttir IJ; Boon NA; Ludlam CA; Fox KA; Newby DE
    J Am Coll Cardiol; 2008 Jul; 52(1):33-9. PubMed ID: 18582632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombin receptor antagonists as novel therapeutic targets.
    Chackalamannil S
    Curr Opin Drug Discov Devel; 2001 Jul; 4(4):417-27. PubMed ID: 11727307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombin-activated receptors: promising targets for cancer therapy?
    García-López MT; Gutiérrez-Rodríguez M; Herranz R
    Curr Med Chem; 2010; 17(2):109-28. PubMed ID: 19941475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives.
    Moschonas IC; Goudevenos JA; Tselepis AD
    Int J Cardiol; 2015 Apr; 185():9-18. PubMed ID: 25777282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombin and protease-activated receptors (PARs) in atherothrombosis.
    Martorell L; Martínez-González J; Rodríguez C; Gentile M; Calvayrac O; Badimon L
    Thromb Haemost; 2008 Feb; 99(2):305-15. PubMed ID: 18278179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy.
    Smith SM; Judge HM; Peters G; Armstrong M; Dupont A; Gaussem P; Storey RF
    Platelets; 2005 Sep; 16(6):340-5. PubMed ID: 16194864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.